Professor, Medicine, Indiana University School of Medicine
Nephrology
Dr. Sharon M. Moe, MD
|
|
Give Review
Dr. Sharon M. Moe works in the field of Nephrology. He researched medicine at University of Illinois College of Medicine. He received awards:"President American Society of Nephrology", "Elected Member" and "Fellow (ASNF)". Doctor Sharon M. Moe, MD has written publications. He has 99 publications published with PubMed. The lastest publication is: 'Proteolytic activation of cholera toxin and Escherichia coli labile toxin by entry into host epithelial cells. Signal transduction by a protease-resistant toxin variant.' Sharon M. Moe, MD accepts Medicare payments and is registered with Medicare.gov.
Publications
- The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial.
- Reduced skeletal muscle function is associated with decreased fiber cross-sectional area in the Cy/+ rat model of progressive Kidney disease.
- Raloxifene improves skeletal properties in an animal model of cystic chronic Kidney disease.
- Bone marrow fat is increased in chronic Kidney disease by magnetic resonance spectroscopy.
- The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial.
- Changes in skeletal collagen cross-links and matrix hydration in high- and low-turnover chronic Kidney disease.
- Anti-Sclerostin Antibody Treatment in a Rat Model of Progressive Renal Osteodystrophy.
- The Kidney Research National Dialogue: Gearing Up to Move Forward.
- Nicotinamide treatment in a murine model of familial tumoral calcinosis reduces serum Fgf23 and raises heart Calcium.
- Pathogenesis of Arrhythmias in a Model of CKD.
- Adipocyte induced arterial calcification is prevented With sodium thiosulfate.
- Predicting the Glomerular Filtration Rate in Bariatric Surgery Patients.
- Influence of Dietary Protein on Glomerular Filtration Before and After Bariatric Surgery: A Cohort Study.
- What have we learned about chronic Kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?
- Adverse Mandibular Bone Effects Associated with Kidney Disease Are Only Partially Corrected with Bisphosphonate and/or Calcium Treatment.
- A comparison of Calcium to zoledronic acid for improvement of cortical bone in an animal model of CKD.
- Recent advances in the noninvasive diagnosis of Renal osteodystrophy.
- Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic Kidney disease.
- Transglutaminase 2 Accelerates Vascular Calcification in Chronic Kidney Disease.
- Rebuttal: PTH--A Particularly Tricky Hormone: Why Measure It at All in Kidney Patients?
- The case for routine parathyroid hormone monitoring.
- Worsening Endothelial Function With Efavirenz Compared to Protease Inhibitors: A 12-Month Prospective Study.
- Comparing mandated health care reforms: the Affordable Care Act, accountable care organizations, and the Medicare ESRD program.
- Skeletal effects of zoledronic acid in an animal model of chronic Kidney disease.
- Calcium Builds Strong Bones, and More Is Better--Correct? Well, Maybe Not.
- Gentamicin Pharmacokinetics and Pharmacodynamics during Short-Daily Hemodialysis.
- Klotho: A Master Regulator of Cardiovascular Disease?
- Vascular Calcification: Pathophysiology and Risk Factors.
- CKD-Mineral and Bone Disorder: Core Curriculum 2011.
- The pathophysiology of early stage chronic Kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.
- Activation of Arterial Matrix Metalloproteinases Leads to Vascular Calcification in Chronic Kidney Disease.
- Calcimimetics inhibit Renal pathology in rodent nephronophthisis.
- Direct effects of phosphate on vascular cell function.
- Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic Kidney disease.
- The KDIGO guideline on dialysate Calcium and patient outcomes: need for hard evidence.
- Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysis.
- Oral phosphate binders in patients with Kidney failure.
- RhoA/Rho kinase (ROCK) alters fetuin-A uptake and regulates calcification in bovine vascular smooth muscle cells (BVSMC).
- Confusion on the complexity of Calcium balance.
- All research does not a guideline make!
- Verapamil inhibits calcification and matrix vesicle activity of bovine vascular smooth muscle cells.
- A randomized trial of cholecalciferol versus doxercalciferol for lowering parathyroid hormone in chronic Kidney disease.
- Calcimimetic inhibits late-stage cyst growth in ADPKD.
- Vascular calcification: the three-hit model.
- A rat model of chronic Kidney disease-mineral bone disorder.
- Annexin-mediated matrix vesicle calcification in vascular smooth muscle cells.
- Improving global outcomes in mineral and bone Disorders.
- Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study.
- Association of hepatitis C virus infection with prevalence and development of Kidney disease.
- Disorders involving Calcium, phosphorus, and magnesium.
- Mechanisms of vascular calcification in chronic Kidney disease.
- Vitamin D, cardiovascular Disease, and survival in dialysis patients.
- Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview.
- Fetuin-A uptake in bovine vascular smooth muscle cells is Calcium dependent and mediated by annexins.
- Management of chronic Kidney disease-mineral bone disorder.
- Chronic Kidney disease-mineral-bone disorder: a new paradigm.
- Management of chronic Kidney disease mineral-bone disorder.
- The case against Calcium-based phosphate binders.
- Fish consumption and omega-3 fatty acid status and determinants in long-term hemodialysis.
- The role of vitamin D in vascular calcification in chronic Kidney disease.
- Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic Kidney disease (CKD).
- Prevalence of calcidiol Deficiency in CKD: a cross-sectional study across latitudes in the United States.
- Calcification or classification?
- Achieving NKF-K/DOQI bone Metabolism and disease treatment goals with cinacalcet HCl.
- Disorders of Calcium, phosphorus, and magnesium.
- Pathophysiology of vascular calcification in chronic Kidney disease.
- Uremic vasculopathy.
- Cinacalcet for secondary Hyperparathyroidism in patients receiving hemodialysis.
- A bridge to improving healthcare outcomes and quality of life.
- Introduction. Renal osteodystrophy.
- Vascular calcification in chronic Kidney disease.
- Effects of sevelamer hydrochloride and Calcium acetate on the oral bioavailability of ciprofloxacin.
- Identity and localization of advanced glycation end products on human beta2-microglobulin using matrix-assisted laser desorption/ionization time-of-flight mass spectro...
- Vascular calcification in dialysis patients: pathogenesis and consequences.
- Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels.
- Arterial calcification in Diabetes.
- The calcimimetic AMG 073 reduces parathyroid hormone and Calcium x phosphorus in secondary hyperparathyroidism.
- Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells.
- Signal transduction of beta2m-induced expression of VCAM-1 and COX-2 in synovial fibroblasts.
- Medial artery calcification in ESRD patients is associated With deposition of bone matrix proteins.
- The effect of a diet containing 70% protein from plants on mineral metabolism and musculoskeletal health in chronic Kidney disease.
- Effects of Cinacalcet on Atherosclerotic and Nonatherosclerotic Cardiovascular Events in Patients Receiving Hemodialysis: The EValuation Of Cinacalcet HCl Therapy to L...
- Cortical bone mechanical properties are altered in an animal model of progressive chronic Kidney disease.
- Hemodialysis does not alter in vitro hepatic CYP3A4 and CYP2D6 metabolic activity in uremic serum.
- Decreased MicroRNA Is Involved in the Vascular Remodeling Abnormalities in Chronic Kidney Disease (CKD).
- Targeting of cholera toxin and Escherichia coli heat labile toxin in polarized epithelia: role of COOH-terminal KDEL.
- Proteolytic activation of cholera toxin and Escherichia coli labile toxin by entry into host epithelial cells. Signal transduction by a protease-resistant toxin variant.
- Signal transduction by cholera toxin: processing in vesicular compartments does not require acidification.
- Early manifestations of "sick euthyroid" syndrome in patients with compensated chronic heart Failure.
- 50 years of research and discovery in chronic Kidney disease and mineral & bone disorder: the central role of phosphate.
- A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing With thrice-daily sevelamer hydrochloride tablet dosing in CKD patient...
- Renal function and bisphosphonate safety.
- Measuring the glomerular filtration rate in obese individuals without overt Kidney disease.
- Acute tubulointerstitial nephritis attributable to indinavir therapy.
- Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO).
- Review of the effects of omega-3 supplementation in dialysis patients.
- Independent influence of dietary protein on markers of Kidney function and disease in obesity.
- Efficacy of sodium thiosulfate for the treatment for calciphylaxis.
Schools
University Of Illinois College Of Medicine Chicago
Loyola University Mc
University Chicago Pritzker School Med
Conditions Treated
- Acute Kidney Failure
- Calcium Metabolism Disorders
- Chronic Kidney Diseases
- Diabetes With Renal Manifestations
- View All
Doctors Specialties
- Nephrology
Accepted Insurances
- Aetna
- Pathway X Bronze Direct CACA IN HIX
- Anthem Blue Cross Blue Shield HMO
- Anthem Blue Cross Blue Shield PPO
- Blue Card PPO
- Blue Cross Blue Shield of Illinois PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- Emblem Health
- First Health (Coventry Health Care) PPO
- Medicare Advantage PFFS
- HealthSmart
- Choice Care PPO
- Mail Handlers Benefit Plan (MHBP)
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Mutual of Omaha
- Sagamore Plus
- Choice Plus POS
- Navigate HMO
- Navigate POS
- Options PPO
- United Healthcare
- Universal American
Awards
- President American Society of Nephrology
- Elected Member
- Fellow (ASNF)
Education
-
University of Chicago -
Loyola University -
University of Illinois College of Medicine
Hospital
-
IU Health Methodist Hospital
Drug Facts
| NPI NUMBER | 1851356547 | |
| NPPES Provider LastName | MOE | |
| NPPES Provider FirstName | SHARON | |
| NPPES Provider ZIPCode | 462022859 | |
| NPPES Provider State | IN | |
| Specialty Description | Nephrology | |
| Total Claim Count | 405.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1851356547 |
| Last Name Of The Provider | MOE |
| First Name Of The Provider | SHARON |
| View All |
Similar Doctors
|
|
Dr. Kathleen A. Prag, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard N. Hellman, MD |
|
Dr. Kashif Manzoor, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajiv Agarwal, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. John P. Lucia, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jay H. Weiss, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Katherine J. Kelly, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Miguel R. Escobar, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sherif M. Elassal, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pierre Dagher, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Douglas R. Maxwell, MD |
|
|
Dr. Ali K. Khalil, MD |
|
Dr. Tae K. Chong, MD |
|
|
Dr. Peter J. Juran, MD
This Doctor is OpenDoctor Recommended.
|